Cleo Diagnostics Ltd (ASX: COV) - Share Price

Current share price for COV : $0.360 0.005 (1.37%)⁺

Cleo Diagnostics Limited (COV), an ASX-listed company, is a biotechnology company that commercializes novel technology for the detection of ovarian cancers.

COV General Information ⁺

ASX Code	COV
Website	http://www.cleodx.com
Industry/Sector	Health Care Equipment
Market Cap ($M)	49
COV Share Price	$0.360
Day High	$0.380
Day Low	$0.335
Last Close	$0.365
COV Share Price Movement	$0.01 ( 1.37% )

Prices as at 16:40, 17 Jul 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Cleo Diagnostics Ltd (COV) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Cleo Diagnostics Ltd (COV) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Cleo Diagnostics Ltd (COV) price-sensitive announcements

COV - CLEO Enters Analytical Validation Phase

Cleo Diagnostics Ltd (ASX:COV) has announced its entry into the analytical validation phas

Cleo Diagnostics Ltd (COV)
13 Jul 2026 | 9:10 AM

COV - CLEO Establishes U.S. Reimbursement Pathway

Cleo Diagnostics Ltd (ASX:COV) has outlined a strategic plan for entering the U.S. market

Cleo Diagnostics Ltd (COV)
20 May 2026 | 9:25 AM

COV - Quarterly activities and cashflow report

Cleo Diagnostics Ltd, trading on the ASX under the ticker COV, provided its quarterly repo

Cleo Diagnostics Ltd (COV)
29 Apr 2026 | 9:32 AM

COV - CLEO Commences Kit Manufacturing Ahead of FDA Submission

Cleo Diagnostics Ltd has embarked on a significant milestone with the commencement of a st

Cleo Diagnostics Ltd (COV)
28 Apr 2026 | 8:26 AM

Cleo Diagnostics Ltd (COV) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Cleo Diagnostics Ltd (COV) ORDINARY FULLY PAID	Health Care	$49	CLEO Enters Analytical Validation Phase	13 Jul 2026 9:10AM	$0.510	$0.360	fallen by 29.41%
Cleo Diagnostics Ltd (COV) ORDINARY FULLY PAID	Health Care	$49	Change in Director's Interest Notice	7 Jul 2026 4:41PM	$0.495	$0.360	fallen by 27.27%
Cleo Diagnostics Ltd (COV) ORDINARY FULLY PAID	Health Care	$49	Cleansing Notice	28 May 2026 4:18PM	$0.585	$0.360	fallen by 38.46%
Cleo Diagnostics Ltd (COV) ORDINARY FULLY PAID	Health Care	$49	Application for quotation of securities - COV	28 May 2026 4:12PM	$0.585	$0.360	fallen by 38.46%
Cleo Diagnostics Ltd (COV) ORDINARY FULLY PAID	Health Care	$49	CLEO Establishes U.S. Reimbursement Pathway	20 May 2026 9:25AM	$0.635	$0.360	fallen by 43.31%
Cleo Diagnostics Ltd (COV) ORDINARY FULLY PAID	Health Care	$49	Quarterly activities and cashflow report	29 Apr 2026 9:32AM	$0.625	$0.360	fallen by 42.40%

COV Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2025A	-$4.00	-$3.10	-2.80%	0.00%	0.0%
2024A	-$3.76	-$3.20	-51.40%	0.00%	0.0%
2023A	-$1.73	-$6.60	21,866.70%	0.00%	0.0%

COV Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A
Cochlear Limited (COH)	$8,062M	0.0171	-0.1883	0.0862	20.5989	25.3773	23.3643	3.49%	2.81%	3.00%
Cleo Diagnostics Ltd (COV)	$50M	-0.0281	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Fisher & Paykel Healthcare Corporation Limited (FPH)	$19,493M	0.1388	0.1347	0.1883	50.1890	44.2297	37.2210	1.31%	1.40%	1.58%
ResMed Inc. (RMD)	$16,834M	0.3087	9.7669	0.0812	194.9106	18.1028	16.7435	1.18%	1.24%	1.31%

COV Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	7.93	0.00
Market	0.31	12.90	1.13	0.58
Sector	0.69	21.40	1.57	1.90

COV Directors

Name	Position	Start Date
Dr Richard Allman	Chief Executive Officer, Managing Director	10 Oct 2022
Dr Andrew Nicholas Stephens	Chief Scientific Officer, Executive Director	19 Sep 2022
Professor Thomas Jobling	Lead Medical Advisor, Non-Executive Director	21 Dec 2022
Mr Adrien Michele Wing	Non-Executive Chairman, Non-Executive Director	11 Aug 2022
Ms Lucinda Nolan	Non-Executive Director	2 Mar 2023

Cleo Diagnostics Ltd (COV) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
14 Apr 2009	MOORE, John	Transfer	Direct Shares	209,420	$0.054	$11,308.680
14 Apr 2009	MOORE, John	Buy	Indirect Shares	40,760	$0.054	$2,201.040
18 Mar 2009	MOORE, John	Buy	Direct Shares	130,000	$0.042	$5,400.000

See all changes in directors' interest & trades for Cleo Diagnostics Ltd (COV) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

COV Management

Name	Position
Pauline M Moffatt	Company Secretary

COV Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Cleo Diagnostics Ltd (COV). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
14,250,000 (11.09%)	Michelle Wing
9,125,000 (7.10%)	Richard Vom
7,189,140 (5.59%)	Hudson Institute Investment Holdings Pty Ltd

COV Calendar of Events

Date	Event
24 February 2027	Report (Interim)
25 August 2026	Report (Annual)
25 August 2026	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us